Abstract Diabetes is a pandemic disease with a higher occurrence in minority populations. The molecular mechanism to initiate diabetes-associated retinal angiogenesis remains largely unknown. We propose an inflammatory pathway of diabetic retinopathy in which macrophages in the diabetic eye provide TGFb to retinal endothelial cells (REC) in the retinal microvasculature. In response to TGFb, REC synthesize and secrete a pro-apoptotic BIGH3 (TGFb-Induced Gene Human Clone 3) protein, which acts in an autocrine loop to induce REC apoptosis. Rhesus monkey retinal endothelial cells (RhREC) were treated with dMCM (cell media of macrophages treated with high glucose and LDL) and assayed for apoptosis (TUNEL), BIGH3 mRNA (qPCR), and protein (Western blots) expressions. Cells were also treated with SGFb1 and 2 for BIGH3 mRNA and protein expression. Inhibition assays were carried out using antibodies for TGFb1 and for BIGH3 to block apoptosis and mRNA expression. BIGH3 in cultured RhREC cells were identified by immunohistochemistry (IHC). Distribution of BIGH3 and macrophages in the diabetic mouse retina was examined with IHC. RhRECs treated with dMCM or TGFb showed a significant increase in apoptosis and BIGH3 protein expression. Recombinant BIGH3 added to RhREC culture medium led to a dose-dependent increase in apoptosis. Antibodies (Ab) directed against BIGH3 and TGFb, as well as TGFb receptor blocker resulted in a significant reduction in apoptosis induced by either dMCM, TGFb or BIGH3. IHC showed that cultured RhREC constitutively expressed BIGH3. Macrophage and BIGH3 protein were co-localized to the inner retina of the diabetic mouse eye. Our results support a novel inflammatory pathway for diabetic retinopathy. This pathway is initiated by TGFb released from macrophages, which promotes synthesis and release of BIGH3 protein by REC and REC apoptosis.
Introduction
Apoptosis of retinal pericyte and retinal endothelial cells has been a major focus of investigation on the cellular pathway of diabetic retinopathy. In an earlier report, diabetes and high glucose were shown to activate nuclear factor-jB in human retinal pericytes (but not in endothelial cells) leading to pericyte apoptosis [1] [2] [3] [4] . In a separate pathway independent of NF-jB, hyperglycemia causes mouse retinal pericyte apoptosis by the activation of PKC-d and MAPK to increase the expression of a protein tyrosine phosphatase (SHP-1) which results in PGDF receptor-b dephosphorylation [2] . High glucose, transforming growth factor beta-1 (TGFb1) and TGFb-Induced Protein (BIGH3), also known as TGF-Beta-Induced Gene Human Clone 3, beta-ig, and keratoepithelin, produced apoptosis in cultured bovine retinal pericytes [3] . In comparison to reports on cellular pathway of diabetic retinopathy associated with retinal pericyte apoptosis, Busik et al. proposed that retinal endothelial cells apoptosis may also be involved in the development of retinal angiogenesis and diabetic retinopathy. In this pathway, hyperglycemia causes other retinal cells to release inflammatory cytokines-IL1b and INFa which induces reactive oxygen species toxicity and apoptosis in retinal endothelial cells [4] .
Diabetic retinopathy and nephropathy are known to be associated with chronic inflammation and macrophage activation [5] [6] [7] . Tissue macrophages constitutively secrete TGFb1 [6] , which is further increased in response to inflammatory stimuli [7] and following phagocytosis of apoptotic cells [5] . TGFb induces the synthesis and secretion of the BIGH3 protein from mesenchymal and other target cells [8, 9] leading to apoptosis. However, a direct link between metabolic stress, macrophage-derived TGFb1 secretion and BIGH3 deposition in inflamed, diabetic ocular tissues has not been explored for a possible pathway on retinal vascular cells apoptosis in diabetic retinopathy.
The human BIGH3 gene is localized on chromosome 5q31. Human BIGH3 protein comprises 683 amino acid residues. In its secreted form BIGH3 has a reported molecular weight of 69 kDa [10] . BIGH3 is a cell-adhesion class protein that has four fasciclin-1 like domains (Fas 1-4) homologous to fasciclin-1, a Drosophila nerve growth cone guidance molecule [8] . There are several different sequences that in vitro are recognized as ligands for integrins, including integrins a3b1, avb3 and avb5 [11] [12] [13] [14] . Endothelial cells use avb5 in cytoplasmic signaling to mediate cell adhesion and migration [15] , suggesting that BIGH3 may provide a site for macrophage adhesion and retention. BIGH3 is expressed by a wide range of cell types: human corneal epithelial cells [13] , human umbilical vein endothelial cells [16] , osteoblasts [11] , and vascular smooth muscle cells [17] . It also functions as a substratum ligand for a number of different integrins on different cell types. In two separate reports, Han et al. showed that the gene for BIGH3 protein is also a diabetes-risk gene affecting pancreatic b-islet cell proliferation based on results from a mouse (in vitro and in vivo KO) model and on human genetic analysis [18, 19] .
Recently, we found that macrophage-conditioned medium is a potent stimulus of BIGH3 synthesis in cultured renal cells (LeBaron et al., manuscript in preparation). In a preliminary study, we have also collected experimental evidence to show that these conditioned media, as well as TGFb, induced overproduction of BIGH3 in retinal endothelial cells and apoptosis (Mondragon et al. ARVO 2012) . Subsequently, we performed detailed in vitro analyses on the response of retinal capillary endothelial cells (RhREC) to macrophage-derived TGFb and to the BIGH3 protein.
Our results indicate that macrophage TGFb increased BIGH3 mRNA and BIGH3 protein synthesis, which led to a dose-dependent increase of RhREC apoptosis. Using an in vivo model, we further confirm the co-localization of macrophages and the BIGH3 protein in the inner retina of the diabetic mice. Thus we propose that macrophageassociated increase in BIGH3 expression induces retinal endothelial cell apoptosis to weaken retinal capillaries leading to angiogenesis and diabetic retinopathy.
Methods

Cell culture
Rhesus Retinal Endothelial Cells (RhREC) were purchased from ATCC (Cat No: CRL-1780, RF/6A). Cells were transformed at an early passage and were maintained in minimum essential media (MEM) as described previously [20] .
Macrophage conditioned medium
Mononuclear cells were isolated from blood obtained from healthy human donors (South Texas Blood and Tissue Center), and mature human monocyte-derived macrophages (HMDM) were prepared as described previously [21] . To generate conditioned media, HMDM were pretreated for 24 h with RPMI medium supplemented with 10 % human AB serum (''healthy'' condition) or RPMI medium supplemented with 10 % human AB serum and with 25 mM D-glucose plus 100 mg/mL freshly isolated human low-density lipoprotein (''diabetic'' condition). After the pre-incubation period, the HMDMs were washed and incubated for 24 h in serum-free RPMI medium. Conditioned media from ''healthy'' macrophages (MCM), and macrophages cultured in ''diabetic condition'' (dMCM) were collected and centrifuged to remove any floating cells. Such conditioned media are hereafter referred to as either ''MCM'' or ''dMCM'' based on the medium in which HMDM were cultured. Aliquots of MCMs were kept at -20°C until use.
Transforming growth factor b
TGFb1 and TGFb2 and small chemical TGFb1 receptor blocker were purchased from Sigma Aldrich (Cat No: T7039, T2815, SB-431542).
Animals
Female LDL-R -/-mice (B6.129S7-LdlrtmIHer/J, Stock No. 002207) on a C57BL/6 J background and C57BL/6 J donor mice were obtained from The Jackson Laboratories (Bar Harbor, ME). After 2 weeks on a maintenance diet (MD, AIN-93G, BioServ), mice were rendered diabetic by intraperitoneal injection of streptozotocin (STZ) (50 mg kg -1 day -1 ) dissolved in citrate buffer (50 mM; pH = 4.5) for five consecutive days and after two day's rest, again for two consecutive days [22] . Non-diabetic mice received a comparable volume of citrate buffer. To induce hypercholesterolemia, mice were fed a high fat diet (HFD) supplemented with fat (21 % wt/wt) and cholesterol (0.15 % wt/wt; AIN-76A, BioServ) beginning 3 weeks after the first STZ injection and continued for a total of 12 weeks. All experiments in the present study conformed to the ARVO (Association for Research in Vision and Ophthalmology) resolution on the humane use of animals in ophthalmic and vision research [23] and were approved by the UTHSCSA-IACUC (Institutional Animal Care and Use Committee). Antibodies BIGH3 bacterial fusion protein was used to immunize New Zealand white rabbits. The resultant anti-BIGH3 antiserum has been previously characterized [24] . Pre-immune serum from the immunized animal was used as negative control where indicated in the individual experiments. Rat anti-CD68 antibody was obtained from ABD seroTec (Cat No. MCA1957T). Mouse anti-TGFb1 antibody (clone 9016) was from R&D Systems.
ELISA
Quantitative enzyme linked immunosorbent assay (ELISA) was performed according to manufacturer's instructions (R&D Systems Cat No: DB100B and DB-250) on different batches of MCM and dMCM to quantify the amount of TGFb1 and TGFb2.
Immunohistochemistry
Eyes from adult MD, HFD and diabetic mice were dissected after mice were euthanized by CO 2 inhalation and cervical luxation [7] . Eyes were embedded in paraffin and frozen at -80°C until use. Eyes were mounted in freezing medium and sections 10 lm thick were mounted on glass microscope slides and fixed for 30 min in 10 % fresh paraformaldehyde in PBS. Fixed sections were rinsed with 20 mM glycine in PBS (Buffer B), blocked for 1 h in 3 % BSA in PBS, and incubated 12 h with anti-BIGH3 (1:200) and anti-CD68 (1:300). After rinsing, sections were incubated for 1 h with anti-rabbit or anti-rat antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 594 fluorescent dyes, respectively. Sections were again rinsed with PBS, and sealed with Vectashield and a glass coverslip. Unless indicated otherwise, all incubations were at ambient temperature, and all rinses were 3 9 15 min in Buffer B. 
Western blotting
Proteins in equal volumes of conditioned media were resolved on reducing 4-10 % SDS polyacrylamide gels and transferred to Immobilon-P membrane. Anti-BIGH3 antibody was incubated (1:5000) with transferred proteins, washed and then incubated with goat anti-rabbit horseradish peroxidase labeled IgG (1:3000). The complex was detected using the substrate diaminobenzidine (DAB). Densitometry was performed using Image J software developed by NIH. [25] ; values were normalized to expression levels of 18s-rRNA.
Results
Cultured RhRECs synthesized and secreted BIGH3
To test whether the retinal vasculature contributes to the synthesis and secretion of BIGH3 protein, an in vitro study was conducted by culturing RhREC in MEMa supplemented with 10 % FBS. Immunohistochemistry (IHC) analyses revealed BIGH3 is synthesized by RhREC in culture. The cells secrete BIGH3 that is found in depositions (Fig. 1a) between cells that have a well-organized actin cytoskeleton (Fig. 1b) . BIGH3 is localized in both the cytosol of the cells and secreted (see also Supplementary  Figure S1 ), into the substratum and the cells' conditioned medium, as expected for soluble extracellular matrix molecules. We therefore proceeded to assess the expression and secretion of the BIGH3 protein by RhREC.
dMCM, TFGb and BIGH3 induced RhREC apoptosis
In a previous study, we reported that macrophages cultured in growth medium with high glucose and high LDL provided an elevated level of TGFb in the conditioned medium. Thus, we hypothesized that macrophage-derived TGFb induces an elevated expression of BIGH3 protein in RhRECs, which when in sufficient amounts will induce apoptosis. RhRECs were cultured in 100 % MEMa, 100 % RPMI or 75 % RPMI ? 25 % dMCM for 24 h and then apoptosis was quantified (See Supplementary Figure  S2 for TUNEL staining images). RhRECs in 25 % dMCM had a 35 % increase (p value \0.01) in apoptosis in comparison to the cells cultured in MEMa and RPMI (Fig. 2a) . Figure 2b shows that TGFb1, when added to cell media, induced apoptosis in 4 % of RhREC in culture while TGFb2 induced 12 % apoptosis. The addition of BIGH3 antibody (Ab) into the cell media reduced the level of RhREC apoptosis induced by TGFb1 and significantly reduced the level of apoptosis by TGFb2 (Fig. 2b) . In a subsequent experiment, RhREC were cultured in 100 % RPMI, 25 % dMCM ? 75 % RPMI, and also co-treated with anti-TGFb1 antibody (TGFb Ab), anti-BIGH3 antiserum (BIGH3 Ab), or TGFb1 receptor inhibitor (RI) as well as their controls (mouse IgG, rabbit serum, and DMSO). The negative control did not block RhREC apoptosis (Fig. 2c) . However, apoptosis induced by dMCM (27 %) was significantly reduced to 8 % by cotreatment with TGFb1 Ab, to 15 % by BIGH3 Ab, and to 10 % by TGFb1 receptor inhibitor, RI (see Fig. 2c ). Furthermore, the addition of recombinant, full length BIGH3 protein to cell media led to a dose-dependent increase in RhREC apoptosis after a 24 h incubation period (Fig. 2d) . These results strongly indicate that dMCM-induced RhREC apoptosis is mediated by TGFb and the BIGH3 protein. RhREC treated with dMCM increased the quantity of BIGH3 mRNA (Fig. 3) . dMCM treatment increased RhREC mRNA expression of BIGH3 from the two control groups of DMSO and mouse IgG (Fig. 3) . The addition of TGFb1 receptor inhibitor (RI) and TGFb1 Ab completely blocked dMCM-induced BIGH3 mRNA expression (Fig. 3a) . dMCM treatment resulted in significantly higher BIGH3 mRNA levels in each of the four time points of 3, 6, 24, and 48 h (Fig. 3b) . A time-dependent increase in BIGH3 expression (from 1 to threefold changes) was observed during the first 24 h of dMCM treatment (Fig. 3b) . Both TGFb1 and TGFb2 had a concentrationdependent effect on BIGH3 expression. An increase in TGFb1 concentration from 0 to10 ng/ml resulted in a five to sixfold increase in BIGH3 mRNA expression (Fig. 3c) . Similarly, concentrations of 0-10 ng/ml TGFb2 increased BIGH3 expression by 3.5 fold (Fig. 3d) .
TGFb 1 and 2 induced BIGH3 protein secretion by RhREC
Results from Western blot analyses on cell media of RhRECs treated with TGFb show an increase in BIGH3 protein synthesis and secretion (Fig. 4a, c) . Comparable concentrations of TGFb1 and TGFb2 induced a similar amount of BIGH3 protein in the cell media (Fig. 4b, d ).
Together with results on TGFb-induced BIGH3 mRNA expressions (see Fig. 3 ), it is apparent that TGF b1 induced about five to sixfold increases in BIGH3 mRNA but only twofold increases in BIGH3 protein secreted into cell media. In contrast, TGFb2 induced a 3.5-fold increase in BIGH3 mRNA and also a two-fold increase of BIGH3 protein in culture media. Irrespective of the difference in transcription and translation/ secretion of the BIGH3 protein, these results clearly show that the cytokine TGFb induced RhREC to significantly increase in BIGH3 protein synthesis and secretion. Diabetes increased macrophages and BIGH3 in the inner retina IHC analyses using anti-CD68 and anti-BIGH3 antibodies revealed increased macrophages and BIGH3 protein in the inner retina of the diabetic mice (Fig. 5e, f vs. Fig. 5a, b) . Macrophage staining was exacerbated throughout the entire retina when LDL-R -/-mice were treated with STZ to induce diabetes (Fig. 5e ). In the diabetic mouse retina, staining showed an increase of BIGH3 and macrophages in the ganglion cell layer, inner nuclear layer, outer nuclear layer, and layers where photoreceptors and pigment epithelium are present (Fig. 5h) . In contrast, the retina of nondiabetic control mice showed little if any macrophage staining (Fig. 5a ) and reduced BIGH3 proteins, particularly in the inner retina (Fig. 5b) . These results suggest a potential link between macrophages and BIGH3 protein accumulation, and their co-localization in the diabetic mouse eye.
Discussion
In the present study, we tested the hypothesis that RhREC overproduction of BIGH3 mediated by macrophagederived TGFb elicits cell apoptosis which promotes tissue damage in the retinal microvasculature. Our results confirm that macrophage-derived TGFb and recombinant BIGH3 induced apoptosis in RhRECs (Fig. 2) . RhREC apoptosis was blocked when macrophage-derived TGFb and BIGH3 proteins were co-treated with TGFb antibody, BIGH3 antibody, or TGFb RI (Fig. 2) . Taken together, our results support a pathway of BIGH3 involvement in retinal endothelial cell apoptosis mediated by macrophage-derived TGFb. This is the first report on a macrophage-mediated inflammatory pathway and RhREC apoptosis on the development of diabetic retinopathy.
It is well known that different cell types express BIGH3 [11, 13, 16, 17, 26] , however there is little known about the expression of BIGH3 in normal or diabetic retina and even less so regarding the underlying mechanisms that increase retinal BIGH3 protein and BIGH3-mediated apoptosis. Cultured RhRECs synthesized and secreted BIGH3 protein ( Fig. 1) and treatment of RhRECs by dMCM (conditioned media from macrophages cultured in ''diabetic condition'') resulted in a significant increase in BIGH3 mRNA (Fig. 3) . Treatment of RhRECs by TGFb also resulted in significant increases in BIGH3 transcript and protein expression (Figs. 3, 4) , suggesting that the macrophage-derived TGFb may be the bridging factor for the increase in BIGH3 synthesis in RhRECs. It is well known that macrophages are a major source of TGFb1 [6] , and we recently determined that active TGFb1 levels were 41-53 pg/mL in MCM and 60-76 pg/mL in dMCM, whereas no detectable amounts were ascertained in conditioned medium of macrophages not treated with high glucose and LDL (LeBaron et al. 2014, unpublished data).
The accumulation of microglia/macrophages in the retina has been linked to hyperglycemia in a rat model [27] . In this study we show that LDL receptor knockout mice (rendered diabetic) had an increase in macrophages in the retina opposed to non-diabetic mice (Fig. 5e, a, respectively) . Consequently, BIGH3 protein expression increased throughout the retina of diabetic mice (Fig. 5f ). BIGH3 noted at the sclera (Fig. 5f ) is consistent with in situ hybridization showing BIGH3 mRNA abundance [28] . These in vivo data provide initial evidence on macrophages and its co-localization with the BIGH3 protein in the diabetic eye.
In the present study, we have demonstrated that in diabetic conditions, human macrophages synthesize TGFb1 to an extent that is sufficient to stimulate BIGH3 synthesis and secretion by RhRECs. Moreover, using a paracrine or autocrine mechanism, the newly synthesized BIGH3 induces a significant increase in the number of apoptotic RhRECs. We have included both TGFb1 and TGFb2 because the latter was found to be significantly higher in the aqueous and vitreous humor from patients with diabetic retinopathy [29, 30] . In the present study, we found that both isomers are potent effectors for the induction of BIGH3 expression and retinal endothelial cell apoptosis (Figs. 2, 3 and 4) . Macrophages secrete TGFb1 even after phagocytosis of apoptotic cells [6] , and in response to inflammatory stimuli [7] and are a source of TGFb1 in this study. However, the origin of TGFb2 in diabetic conditions in the retina is not readily apparent. It is possible that TGFb2 is derived from activated retinal microglia [31] or monocyte derived macrophages (dMCM contained a similar level of total and mature TGFb1 and TGFb2, unpublished results). Therefore, further study on the role of both isoforms of TGFb is essential to fully explore its role in this novel pathway of retinopathy development. Moreover, transgenic mice lacking BIGH3 may provide insight on its significance in the development of diabetic retinopathy. 
